TY - JOUR
T1 - Timing and Targeting of Treatment in Left Ventricular Hypertrophy
AU - Nam, Deokhwa
AU - Reineke, Erin L.
N1 - Copyright:
This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PY - 2017/1/1
Y1 - 2017/1/1
N2 - In most clinical cases, left ventricular hypertrophy (LVH) occurs over time from persistent cardiac stress. At the molecular level, this results in both transient and long-term changes to metabolic, sarcomeric, ion handling, and stress signaling pathways. Although this is initially an adaptive change, the mechanisms underlying LVH eventually lead to maladaptive changes including fibrosis, decreased cardiac function, and failure. Understanding the regulators of long-term changes, which are largely driven by transcriptional remodeling, is a crucial step in identifying novel therapeutic targets for preventing the downstream negative effects of LVH and treatments that could reverse or prevent it. The development of effective therapeutics, however, will require a critical understanding of what to target, how to modify important pathways, and how to identify the stage of pathology in which a specific treatment should be used.
AB - In most clinical cases, left ventricular hypertrophy (LVH) occurs over time from persistent cardiac stress. At the molecular level, this results in both transient and long-term changes to metabolic, sarcomeric, ion handling, and stress signaling pathways. Although this is initially an adaptive change, the mechanisms underlying LVH eventually lead to maladaptive changes including fibrosis, decreased cardiac function, and failure. Understanding the regulators of long-term changes, which are largely driven by transcriptional remodeling, is a crucial step in identifying novel therapeutic targets for preventing the downstream negative effects of LVH and treatments that could reverse or prevent it. The development of effective therapeutics, however, will require a critical understanding of what to target, how to modify important pathways, and how to identify the stage of pathology in which a specific treatment should be used.
KW - gene regulation
KW - left ventricular hypertrophy
KW - molecular cardiac control
KW - transcription
UR - http://www.scopus.com/inward/record.url?scp=85029674633&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029674633&partnerID=8YFLogxK
U2 - 10.14797/mdcj-13-1-9
DO - 10.14797/mdcj-13-1-9
M3 - Review article
C2 - 28413576
AN - SCOPUS:85029674633
VL - 13
SP - 9
EP - 14
JO - Methodist DeBakey cardiovascular journal
JF - Methodist DeBakey cardiovascular journal
SN - 1947-6094
IS - 1
ER -